Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.61 +1.3%	$1.44	$1.05 ▼ $5.17	$174.33M	0.38	1.18 million shs	650,344 shs
ATBPD Antibe Therapeutics		$0.22	$2.64 ▼ $3.50	$1.21B	0.57	29,710 shs	N/A
PMVP PMV Pharmaceuticals	$1.33	$1.06	$0.81 ▼ $1.82	$69.10M	1.49	198,298 shs	172,565 shs
SUPN Supernus Pharmaceuticals	$32.34 -3.7%	$32.41	$27.05 ▼ $40.28	$1.81B	0.7	492,435 shs	690,515 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	+2.55%	+13.38%	+41.23%	+21.97%
ATBPD Antibe Therapeutics	0.00%	0.00%	0.00%	0.00%	-0.19%
PMVP PMV Pharmaceuticals	0.00%	+5.56%	+20.91%	+30.39%	-17.39%
SUPN Supernus Pharmaceuticals	0.00%	-2.36%	-1.88%	+5.14%	+11.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	1.7876 of 5 stars	3.6	1.0	0.0	0.0	1.1	1.7	0.6
ATBPD Antibe Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	2.4751 of 5 stars	3.5	3.0	0.0	0.0	0.6	2.5	0.6
SUPN Supernus Pharmaceuticals	3.1763 of 5 stars	2.2	1.0	0.0	4.1	3.3	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$8.71	441.26% Upside
ATBPD Antibe Therapeutics	0.00	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	3.00	Buy	$5.50	313.53% Upside
SUPN Supernus Pharmaceuticals	2.33	Hold	$36.00	11.32% Upside

Current Analyst Ratings Breakdown

Latest ACRS, ATBPD, SUPN, and PMVP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ACRS Aclaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	9.31	N/A	N/A	$1.44 per share	1.12
ATBPD Antibe Therapeutics	$7.51M	0.00	N/A	N/A	$0.10 per share	0.00
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$3.40 per share	N/A
SUPN Supernus Pharmaceuticals	$661.82M	2.74	$4.17 per share	7.75	$18.76 per share	1.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-732.42%	-30.73%	-22.74%	8/6/2025 (Estimated)
ATBPD Antibe Therapeutics	-$14.54M	-$0.60	N/A	N/A	N/A	-273.96%	-150.49%	-98.51%	N/A
PMVP PMV Pharmaceuticals	-$58.71M	-$1.18	0.00	N/A	N/A	N/A	-32.54%	-29.59%	8/6/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$73.86M	$1.11	29.14	22.46	N/A	9.27%	12.23%	9.17%	8/5/2025 (Estimated)

Latest ACRS, ATBPD, SUPN, and PMVP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PMVP PMV Pharmaceuticals	-$0.39	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.14	N/A	N/A	N/A	$1.34 million	N/A
8/5/2025	Q2 2025	SUPN Supernus Pharmaceuticals	$0.47	N/A	N/A	N/A	$154.06 million	N/A
5/9/2025	Q1 2025	PMVP PMV Pharmaceuticals	-$0.37	-$0.34	+$0.03	-$0.34	N/A	N/A
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
ATBPD Antibe Therapeutics	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	5.06	5.06
ATBPD Antibe Therapeutics	N/A	5.97	5.42
PMVP PMV Pharmaceuticals	N/A	16.75	16.75
SUPN Supernus Pharmaceuticals	N/A	2.44	2.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
ATBPD Antibe Therapeutics	N/A
PMVP PMV Pharmaceuticals	90.20%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
ATBPD Antibe Therapeutics	N/A
PMVP PMV Pharmaceuticals	7.60%
SUPN Supernus Pharmaceuticals	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
ATBPD Antibe Therapeutics	47	387.00 million	N/A	Not Optionable
PMVP PMV Pharmaceuticals	50	51.95 million	48.01 million	Optionable
SUPN Supernus Pharmaceuticals	580	55.99 million	51.06 million	Optionable

ACRS, ATBPD, SUPN, and PMVP Headlines

Recent News About These Companies

Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen

July 20 at 2:50 AM | marketbeat.com

Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today

July 18 at 12:30 AM | msn.com

Tributary Capital Management LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

July 17 at 8:18 AM | marketbeat.com

Principal Financial Group Inc. Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

July 15, 2025 | marketbeat.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

July 14, 2025 | businesswire.com

Rice Hall James & Associates LLC Sells 12,456 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

July 14, 2025 | marketbeat.com

Stephens Investment Management Group LLC Has $56.94 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

July 13, 2025 | marketbeat.com

Wall Street Zen Upgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Buy

July 12, 2025 | marketbeat.com

2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with Caution

July 10, 2025 | finance.yahoo.com

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)

July 9, 2025 | msn.com

Meritage Portfolio Management Acquires 10,622 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

July 4, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. (SUPN) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

8,151 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Robeco Institutional Asset Management B.V.

July 3, 2025 | marketbeat.com

Sage Sacks Entire Staff After Supernus Buyout

June 30, 2025 | biospace.comB

Supernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions

June 27, 2025 | msn.com

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years

June 23, 2025 | uk.finance.yahoo.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Hold Rating by Wall Street Zen

June 21, 2025 | marketbeat.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18, 2025 | businesswire.com

Supernus Pharma to Buy Sage Therapeutics for Up to $795 Million

June 16, 2025 | marketwatch.com

Supernus enters depression drug market with up to $795 million Sage deal

June 16, 2025 | msn.com

Supernus to acquire depression drugmaker Sage

June 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS, ATBPD, SUPN, and PMVP Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.61 +0.02 (+1.26%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.56 -0.05 (-3.11%)

As of 07/18/2025 07:44 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Antibe Therapeutics OTCMKTS:ATBPD

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

PMV Pharmaceuticals NASDAQ:PMVP

$1.33 0.00 (0.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.32 -0.02 (-1.13%)

As of 07/18/2025 06:22 PM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Supernus Pharmaceuticals NASDAQ:SUPN

$32.34 -1.25 (-3.72%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$32.34 0.00 (0.00%)

As of 07/18/2025 04:34 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time